You might not think it possible to assemble large, longitudinal cohorts of loyal study subjects for rare dementias marked by apathy and emotional blunting. Think again—at the International Conference for Frontotemporal Dementia, researchers showed that they just did it.
Confirming hints from case reports, the Genetic FTD Initiative, a European-Canadian frontotemporal dementia network, shows which brain areas change long before tau, progranulin, and C9ORF72 mutation carriers become symptomatic.
Scientific advances fire up researchers at FTD meeting in a dreary Vancouver.
By beaming red light at a blood sample and measuring the scattered photons, scientists claim to identify people with Alzheimer’s disease.
Two trials suggest that a fixed combination of a cough medicine and a cardiac arrhythmia medicine might treat agitation and quiet emotional outbursts in people with Alzheimer’s.
Using a rarely implemented in vitro fertilization procedure, a woman whose family carries a presenilin mutation delivered twins who are virtually assured of escaping early onset Alzheimer’s disease.
MGH meeting traces arc of scientific discoveries from 1980s to today’s cutting edge.
Researchers are ramping up efforts to target tau for Alzheimer’s and other tauopathies.
Does a tau-based early diagnosis look more likely?
An active immunotherapy is coming to the fore as researchers continue to try novel therapies.
Could exosomes—tiny parcels extruded from cells—make for a blood-based Alzheimer’s marker?
Lifestyle changes to evade dementia, such as healthy eating and exercise, made a strong showing at the Alzheimer’s Association International Conference in Copenhagen, Denmark.
New data strengthens the evidence that dementia risk is dropping in developed countries, possibly due to better education and heart health.
A global effort to combat dementia has been conducting a yearlong series of events. Alzforum spoke with Dennis Gillings, who chairs the new World Dementia Council.
A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.